CHIMERA

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Nov 20, 2023 → Oct 27, 2026

Cited window

Jul 28, 2026 → Oct 27, 2026

Retrieved

Oct 31, 2026

Title

Phase II Study of Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed as Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)

Registry

NCT06155279

Study IDs

IOV-Me-01-2023-CHIMERA

Sponsor

Istituto Oncologico Veneto IRCCS

Collaborators

MSD Italia S.r.l.

Design

Phase 2 · Interventional, single group

Status

Active, not recruiting

Enrollment

41 actual

Registered

2023-12-04

Start

2024-11-06 actual

Primary completion

2025-12-22 actual

Primary endpoint

Primary endpoint - To evaluate the activity of neo-adjuvant treatment by the determination of pathological complete response rate (pCR)

Interventions

1 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –For 5 recordings, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –3 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –The named clinical interpretation comes from a speaker. The video, podcast account and publisher summaries should not be counted as independent HCP agreement.
• –Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
• –Some other videos considered for this edition lacked fully checked speaker-by-speaker transcripts, limiting coverage beyond the named account summarized here.
• –No separate full protocol, exact-trial results publication or exact regulatory label for the complete regimen was identified in the reviewed materials. Registry methods and interview reporting cannot resolve all result-denominator questions or establish regulatory status.
• –The podcast transcript contains an enrollment discrepancy, while the video account reports 41 enrolled patients. No reconciliation is available.
• –No substantive safety or tolerability assessment, survival interpretation or completed predictive patient-selection result was identified in the assessed statements. These absences are not evidence of safety, lack of survival benefit or absence of a benefiting subgroup.

How reports are built and checked: Methods.

Last checked for new commentary Oct 31, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "CHIMERA" (NCT06155279), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "chimera-06155279". If you cannot make requests, read https://www.erudio.com/reports/chimera-nct06155279.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT06155279", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct06155279 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/chimera-nct06155279.json
curl https://www.erudio.com/reports/chimera-nct06155279.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "chimera-06155279" })